Rhumbline Advisers Purchases 23,171 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Rhumbline Advisers grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIXGet Rating) by 9.1% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 278,435 shares of the company’s stock after buying an additional 23,171 shares during the period. Rhumbline Advisers owned 0.29% of Neurocrine Biosciences worth $27,142,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. IndexIQ Advisors LLC bought a new stake in shares of Neurocrine Biosciences in the 1st quarter valued at about $27,000. Acadian Asset Management LLC bought a new stake in shares of Neurocrine Biosciences in the 1st quarter valued at about $27,000. Covestor Ltd boosted its holdings in shares of Neurocrine Biosciences by 431.0% in the 1st quarter. Covestor Ltd now owns 377 shares of the company’s stock valued at $35,000 after buying an additional 306 shares in the last quarter. Quadrant Capital Group LLC boosted its holdings in shares of Neurocrine Biosciences by 6,483.3% in the 1st quarter. Quadrant Capital Group LLC now owns 395 shares of the company’s stock valued at $37,000 after buying an additional 389 shares in the last quarter. Finally, Prospera Financial Services Inc bought a new stake in shares of Neurocrine Biosciences in the 1st quarter valued at about $46,000. 93.18% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NBIX. Barclays raised their price target on shares of Neurocrine Biosciences from $110.00 to $113.00 and gave the company an “overweight” rating in a report on Friday, August 5th. Robert W. Baird lifted their target price on shares of Neurocrine Biosciences from $125.00 to $150.00 in a research note on Wednesday, November 2nd. UBS Group started coverage on shares of Neurocrine Biosciences in a research note on Tuesday, October 11th. They issued a “buy” rating and a $136.00 target price for the company. TheStreet upgraded shares of Neurocrine Biosciences from a “c+” rating to a “b” rating in a research note on Tuesday, November 1st. Finally, Mizuho lifted their target price on shares of Neurocrine Biosciences from $105.00 to $116.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 2nd. Seven investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Neurocrine Biosciences has an average rating of “Moderate Buy” and a consensus price target of $124.00.

Neurocrine Biosciences Price Performance

NASDAQ:NBIX opened at $118.97 on Thursday. The firm has a market cap of $11.44 billion, a price-to-earnings ratio of 208.72 and a beta of 0.52. The company has a 50 day moving average price of $112.30 and a 200-day moving average price of $102.16. Neurocrine Biosciences, Inc. has a 1-year low of $71.88 and a 1-year high of $125.99.

Insider Activity

In other news, insider Eric Benevich sold 24,593 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, November 8th. The shares were sold at an average price of $125.33, for a total transaction of $3,082,240.69. Following the completion of the transaction, the insider now directly owns 15,643 shares of the company’s stock, valued at approximately $1,960,537.19. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, insider Eric Benevich sold 24,593 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, November 8th. The shares were sold at an average price of $125.33, for a total transaction of $3,082,240.69. Following the completion of the transaction, the insider now directly owns 15,643 shares of the company’s stock, valued at approximately $1,960,537.19. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider David W. Boyer sold 1,437 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $106.59, for a total transaction of $153,169.83. Following the transaction, the insider now directly owns 4,214 shares of the company’s stock, valued at $449,170.26. The disclosure for this sale can be found here. Insiders sold a total of 70,531 shares of company stock valued at $8,403,796 in the last three months. 4.40% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Company Profile

(Get Rating)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

See Also

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.